Investors

o2H ventures operates an EIS and SEIS fund focused on seed stage companies covering novel drug discovery and digital therapeutics.

The o2h human health knowledge intensive EIS fund focuses on investing in early-stage companies covering novel drug discovery, artificial intelligence, digital therapeutics, and enabling services.

o2h ventures operates the o2h human health EIS fund focused on early stage biotech therapeutics and AI opportunities.

re.Mind Capital is a mental health venture capital fund associated with Apeiron Investment Group.

Re:cap is a Berlin-based fintech operating the Capital Operating System, providing non-dilutive funding models across European SaaS and fintech ecosystems.

redalpine is a Swiss venture capital firm with over €1bn in assets under management that invests in European software and science companies. The firm operates from offices in Zurich and Berlin.